Top Markets
#1 Black Phoenix Black Phoenix +198.17%
#2 Islamic Coin Islamic Coin +158.03%
#3 Glidr Glidr +84.34%
#4 BasedHype BasedHype +38.64%
#5 Gold Park Gold Park +37.95%
#6 Acurast Acurast +29.31%
#7 Cryptopia Cryptopia +21.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +15.62%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +13.63%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
Classifica tra le azioni #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Prezzo delle azioni
$0.00042815
Ultima sincronizzazione: 2024-02-27
Capitalizzazione di mercato
$13.55K
Variazione (1 giorno)
0.03%
Variazione (1 anno)
0.00%
Paese
GB
Scambia ReNeuron Group plc (RENE)

Categoria

Healthcare
Rapporto P/B per ReNeuron Group plc (RENE)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ReNeuron Group plc, il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per ReNeuron Group plc da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE